IL314322A - Methods of treating patients with autoantibody-mediated disease - Google Patents
Methods of treating patients with autoantibody-mediated diseaseInfo
- Publication number
- IL314322A IL314322A IL314322A IL31432224A IL314322A IL 314322 A IL314322 A IL 314322A IL 314322 A IL314322 A IL 314322A IL 31432224 A IL31432224 A IL 31432224A IL 314322 A IL314322 A IL 314322A
- Authority
- IL
- Israel
- Prior art keywords
- autoantibody
- methods
- mediated disease
- treating patients
- patients
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N2015/1006—Investigating individual particles for cytology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N2015/1486—Counting the particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/54—Determining the risk of relapse
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Rehabilitation Therapy (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Transplantation (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263266852P | 2022-01-17 | 2022-01-17 | |
| PCT/EP2023/050980 WO2023135321A1 (en) | 2022-01-17 | 2023-01-17 | Methods for treating patients with an autoantibody-mediated disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL314322A true IL314322A (en) | 2024-09-01 |
Family
ID=85036487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL314322A IL314322A (en) | 2022-01-17 | 2023-01-17 | Methods of treating patients with autoantibody-mediated disease |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240369467A1 (https=) |
| EP (1) | EP4466539A1 (https=) |
| JP (1) | JP2025504815A (https=) |
| KR (1) | KR20240134900A (https=) |
| CN (1) | CN118556187A (https=) |
| AR (1) | AR128284A1 (https=) |
| AU (1) | AU2023207461A1 (https=) |
| CA (1) | CA3241453A1 (https=) |
| IL (1) | IL314322A (https=) |
| MX (1) | MX2024007806A (https=) |
| TW (1) | TW202333791A (https=) |
| WO (1) | WO2023135321A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3081144A1 (en) | 2017-12-08 | 2019-06-13 | Argenx Bvba | Use of fcrn antagonists for treatment of generalized myasthenia gravis |
| US12202900B2 (en) | 2018-06-08 | 2025-01-21 | argenx BV | Compositions and methods for treating immune thrombocytopenia |
| JP2023509195A (ja) | 2020-01-08 | 2023-03-07 | アルジェニクス ビーブイ | 天疱瘡症を治療する方法 |
| CN119698429A (zh) | 2022-06-15 | 2025-03-25 | 阿根思有限公司 | Fcrn结合分子及使用方法 |
| TW202421195A (zh) * | 2022-11-07 | 2024-06-01 | 比利時商阿根思公司 | 使用fcrn拮抗劑治療狼瘡性腎炎之方法 |
| WO2025093717A1 (en) * | 2023-10-31 | 2025-05-08 | Immunovant Sciences Gmbh | Methods of improving anti-fcrn therapies |
| WO2025202714A1 (en) * | 2024-03-26 | 2025-10-02 | argenx BV | Methods for treating primary sjogren's syndrome using fcrn antagonists |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2158318A2 (en) | 2007-05-14 | 2010-03-03 | Biogen Idec MA, Inc. | Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto |
| KR102904658B1 (ko) * | 2017-12-13 | 2025-12-29 | 모멘타 파머슈티컬스 인코포레이티드 | FcRn 항체 및 이의 사용 방법 |
| JP2023509195A (ja) * | 2020-01-08 | 2023-03-07 | アルジェニクス ビーブイ | 天疱瘡症を治療する方法 |
-
2023
- 2023-01-17 KR KR1020247023836A patent/KR20240134900A/ko active Pending
- 2023-01-17 CA CA3241453A patent/CA3241453A1/en active Pending
- 2023-01-17 MX MX2024007806A patent/MX2024007806A/es unknown
- 2023-01-17 JP JP2024541851A patent/JP2025504815A/ja active Pending
- 2023-01-17 AR ARP230100108A patent/AR128284A1/es unknown
- 2023-01-17 AU AU2023207461A patent/AU2023207461A1/en active Pending
- 2023-01-17 EP EP23701274.5A patent/EP4466539A1/en active Pending
- 2023-01-17 IL IL314322A patent/IL314322A/en unknown
- 2023-01-17 TW TW112102126A patent/TW202333791A/zh unknown
- 2023-01-17 CN CN202380017265.XA patent/CN118556187A/zh active Pending
- 2023-01-17 WO PCT/EP2023/050980 patent/WO2023135321A1/en not_active Ceased
-
2024
- 2024-07-16 US US18/774,570 patent/US20240369467A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023135321A1 (en) | 2023-07-20 |
| MX2024007806A (es) | 2024-07-04 |
| AR128284A1 (es) | 2024-04-10 |
| AU2023207461A1 (en) | 2024-07-11 |
| EP4466539A1 (en) | 2024-11-27 |
| CN118556187A (zh) | 2024-08-27 |
| JP2025504815A (ja) | 2025-02-19 |
| CA3241453A1 (en) | 2023-07-20 |
| TW202333791A (zh) | 2023-09-01 |
| US20240369467A1 (en) | 2024-11-07 |
| KR20240134900A (ko) | 2024-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL314322A (en) | Methods of treating patients with autoantibody-mediated disease | |
| IL277333A (en) | Methods for treating eye diseases | |
| GB202314527D0 (en) | New treatment for pain | |
| SG11202104663PA (en) | Treatment of nsclc patients refractory for anti-pd-1 antibody | |
| IL288677A (en) | Methods for treating Fabry disease in patients with kidney failure | |
| IL315480A (en) | Compounds and methods for treating disease | |
| IL281439A (en) | Combined treatment for blood cancer | |
| GB202406210D0 (en) | Treatment methods for als patients | |
| IL299339A (en) | Antibodies and methods for treating claudin-related diseases | |
| SG11202106794WA (en) | Method for treating lower back pain | |
| IL317947A (en) | Complementary disease treatment methods | |
| GB202006072D0 (en) | Method of selecting patients for treatment with cmbination therapy | |
| GB201908565D0 (en) | Method of stratifying subjects into sub-groups for therapeutic treatment | |
| IL290770A (en) | Compounds and methods for treating oxalate-related diseases | |
| IL305780A (en) | Cancer treatment methods | |
| HK40119747A (en) | Methods for treating patients with an autoantibody-mediated disease | |
| IL281016A (en) | Methods to reduce the risk of diabetes in patients treated for diseases related to high cholesterol | |
| IL326065A (en) | Methods of treating medical conditions and diseases | |
| IL316776A (en) | Methods of treating Pompe disease | |
| ZA202209505B (en) | Snare for treating heart diseases | |
| IL280964A (en) | Diagnosis method for diseases associated with reduced bone density | |
| ES3063909T3 (en) | Method for identifying cancer patients that benefit from anti-clever-1 treatment | |
| GB202302480D0 (en) | shRNA for the treatment of disease | |
| GB202312427D0 (en) | Treatment for autoimmune disease | |
| CA229228S (en) | Lamp for medical use |